M
Malcolm M. DeCamp
Researcher at University of Wisconsin-Madison
Publications - 97
Citations - 5287
Malcolm M. DeCamp is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Lung cancer & Pneumonectomy. The author has an hindex of 28, co-authored 97 publications receiving 4408 citations. Previous affiliations of Malcolm M. DeCamp include Northwestern University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Michael C. Dobelbower,Robert C. Doebele,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Leah J. Leisch,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +34 more
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Journal ArticleDOI
Predictors of mortality in patients with emphysema and severe airflow obstruction.
Fernando J. Martinez,Gregory L. Foster,Jeffrey L. Curtis,Gerard J. Criner,Gail Weinmann,Alfred P. Fishman,Malcolm M. DeCamp,Joshua O. Benditt,Frank C. Sciurba,Barry J. Make,Zab Mohsenifar,Philip T. Diaz,Eric A. Hoffman,Robert A. Wise +13 more
TL;DR: Although patients with advanced emphysema experience significant mortality, subgroups based on age, oxygen utilization, physiologic measures, exercise capacity, and emphySEma distribution identify those at increased risk of death.
Journal ArticleDOI
Assessment of Operative Risk in Patients Undergoing Lung Resection* Importance of Predicted Pulmonary Function
TL;DR: A low predicted postoperative FEV1 appears to be the best indicator of patients at high risk for complications, and it was the only significant correlate of complications when the effect of other potential risk factors was controlled for in a multivariate analysis.
Journal ArticleDOI
Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment Trial Research Group
Keith S. Naunheim,Douglas E. Wood,Zab Mohsenifar,Alice L. Sternberg,Gerard J. Criner,Malcolm M. DeCamp,Claude Deschamps,Fernando J. Martinez,Frank C. Sciurba,James Tonascia,Alfred P. Fishman +10 more
TL;DR: Effects of LVRS are durable, and it can be recommended for upper-lobe-predominant emphysema patients with low exercise capacity and should be considered for palliation in patients with upper- lobe emphySEma and high exercise capacity.
Journal ArticleDOI
The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis.
Robert J. Cerfolio,José Ribas Milanez de Campos,Ayesha S. Bryant,Cliff P. Connery,Daniel L. Miller,Malcolm M. DeCamp,Robert McKenna,Mark J. Krasna +7 more
TL;DR: These studies suggest that primary hyperhidrosis of the extremities, axillae or face is best treated by endoscopic thoracic sympathectomy (ETS), and an international nomenclature should be adopted that refers to the rib levels instead of the vertebral level at which the nerve is interrupted, and how the chain is interrupted.